Stifel raised the firm’s price target on Exact Sciences (EXAS) to $80 from $67 and keeps a Buy rating on the shares. With a Q3 top-line beat and the accompanying guidance raise, Exact’s screening business is now on track to grow revenues by 20%, which is quite a bit higher than the 13% level that management started the year with, the analyst tells investors in a post-earnings note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences: Strong Growth Potential and Strategic Initiatives Justify Buy Rating
- Exact Sciences price target raised to $77 from $65 at Barclays
- Exact Sciences: Strong Q3 Performance and Promising Outlook Drive Buy Rating and Increased Price Target
- Exact Sciences Reports Record Q3 Revenue and Raises Guidance
- Closing Bell Movers: Palantir down 3% after earnings